Boston prevails in stent patent tussle with Johnson & Johnson
This article was originally published in Clinica
Johnson & Johnson last week suffered a knock-back in an ongoing stent war with rival Boston Scientific when a US district court upheld a July 2005 ruling which found J&J's Cypher drug-eluting stent (DES) to have infringed a Boston patent. Dubbed "Ding", the patent covers a two-layer drug coating technology. Aside from denying J&J's motion to overturn the previous verdict, the court also validated the patent.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
How do notified bodies ensure that their personnel, and the teams they allocate for conformity assessment of medical devices, have the precise knowledge and expertise needed? A new EU document gives guidance on this.